Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 4, pp. 705-710
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy
Suzanne L. Topalian, Patrick M. Forde, Leisha A. Emens, et al.
Cancer Cell (2023) Vol. 41, Iss. 9, pp. 1551-1566
Open Access | Times Cited: 129
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 26
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Da Miao, Jing Zhao, Ying Han, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 23-46
Open Access | Times Cited: 35
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Elizabeth G. Dunne, Cameron N. Fick, James M. Isbell, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 119-129
Closed Access | Times Cited: 13
Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?
K Sugiyama, Anderley Gordon, Sanjay Popat, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104122-104122
Closed Access | Times Cited: 1
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
Yong Liu
World Journal of Gastroenterology (2023) Vol. 29, Iss. 34, pp. 5020-5037
Open Access | Times Cited: 13
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges
Angelica D’Aiello, Brendon M. Stiles, Nitin Ohri, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 3, pp. 197-214
Closed Access | Times Cited: 5
Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies
Pernelle Lavaud, Martina Bortolot, Lodovica Zullo, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2779-2779
Open Access | Times Cited: 5
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial
Mariano Provencio, Ernest Nadal, Amelia Insa, et al.
The Lancet Oncology (2024)
Open Access | Times Cited: 5
A Pathologically Friendly Strategy for Determining the Organ‐specific Spatial Tumor Microenvironment Topology in Lung Adenocarcinoma Through the Integration of snRandom‐seq and Imaging Mass Cytometry
Xuqi Sun, Xiao Teng, Chuan Liu, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Closed Access | Times Cited: 4
Ginsenoside Rg3 targets glycosylation of PD-L1 to enhance anti-tumor immunity in non-small cell lung cancer
Wei Wang, Min Kong, Fu Shen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen, Fei Qi, Chao Sun, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Surgical Techniques for Non-Small-Cell Lung Cancer After Neoadjuvant Chemo-Immunotherapy: State of Art and Review of the Literature
Beatrice Trabalza Marinucci, Massimiliano Mancini, Alessandra Siciliani, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 638-638
Open Access
Adjuvant and neo-adjuvant therapy for non-small cell lung cancer without EGFR mutations or ALK rearrangements
Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka
International Journal of Clinical Oncology (2024) Vol. 30, Iss. 2, pp. 215-228
Closed Access | Times Cited: 3
Immunological Mechanisms behind Anti-PD-1/PD-L1 Immune Checkpoint Blockade: Intratumoral Reinvigoration or Systemic Induction?
Guo Zhikun, Jiangnan Yu, Zihan Chen, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 764-764
Open Access | Times Cited: 3
Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer
Yuichiro Tsukada, Hideaki Bando, Koji Inamori, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 2, pp. 283-289
Closed Access | Times Cited: 3
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
Maite Álvarez, Carmen Molina, Saray Garasa, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study
Hanbo Pan, Ningyuan Zou, Yu Tian, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Perioperative immunotherapy for resectable non-small-cell lung cancer
Xiaodong Yang, Dongliang Bian, Jie Yang, et al.
Clinical Cancer Bulletin (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 2
Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC
Evangelia Bogatsa, George Lazaridis, Chrysoula Stivanaki, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1619-1619
Open Access | Times Cited: 2
Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer
Sabrina Rossi, Silvia Masini, Giovanna Finocchiaro, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1683-1683
Open Access | Times Cited: 2
Recent Advances in Perioperative Immunotherapies in Lung Cancer
Shota Fukuda, Kenichi Suda, Akira Hamada, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1377-1377
Open Access | Times Cited: 6
Analysis of PD-L1 promoter methylation combined with immunogenic context in pancreatic ductal adenocarcinoma
Xinyuan Chen, Shuangni Yu, Jie Chen, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 2
Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review
Siyuan Cui, Na Wang, Yangyueying Liang, et al.
International Immunopharmacology (2024) Vol. 141, pp. 112903-112903
Closed Access | Times Cited: 2
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
Jay Parekh, Kaushal Parikh, Joshua E. Reuss, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 8, pp. 913-922
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top